ARS Pharmaceuticals (SPRY) Other financing activities (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted Other financing activities of $62000.0 for Q1 2026, down 96.52% sequentially from $1.8 million in Q4 2025, and down 91.45% YoY from $725000.0 in Q1 2025.
ARS Pharmaceuticals (SPRY) Other financing activities (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported Other financing activities for 7 years, with the latest figure at $62000.0 in Q1 2026.
- Quarterly Other financing activities fell 91.45% year-over-year to $62000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (up 44.07% YoY) and the FY2025 annual result came in at $5.7 million, up 88.36% from the prior year.
- Other financing activities declined to $62000.0 in Q1 2026 per SPRY's latest filing, from $1.8 million in the prior quarter.
- Over five years, Other financing activities peaked at $2.9 million in Q2 2023 and troughed at $62000.0 in Q1 2026.
- A 5-year average of $1.1 million and a median of $725000.0 in 2025 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2023 and 2026: Other financing activities jumped 894.43% in 2023, then slumped 91.45% in 2026.
- Over 5 years, Other financing activities stood at $283000.0 in 2022, then surged by 537.81% to $1.8 million in 2023, then declined by 15.07% to $1.5 million in 2024, then gained by 16.11% to $1.8 million in 2025, then plunged by 96.52% to $62000.0 in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $62000.0, $1.8 million, and $479000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 786,000.00 |
| Jun 30, 2026 | 786,000.00 |
| Mar 31, 2026 | 62,000.00 |
| Mar 31, 2026 | 62,000.00 |
| Dec 31, 2025 | 1.78 Mn |
| Dec 31, 2025 | 1.78 Mn |
| Sep 30, 2025 | 479,000.00 |
| Sep 30, 2025 | 479,000.00 |
| Jun 30, 2025 | 2.70 Mn |
| Jun 30, 2025 | 2.70 Mn |
| Mar 31, 2025 | 725,000.00 |
| Mar 31, 2025 | 725,000.00 |
| Dec 31, 2024 | 1.53 Mn |
| Dec 31, 2024 | 1.53 Mn |
| Sep 30, 2024 | 680,000.00 |
| Sep 30, 2024 | 680,000.00 |
| Jun 30, 2024 | 545,000.00 |
| Jun 30, 2024 | 545,000.00 |
| Mar 31, 2024 | 258,000.00 |
| Mar 31, 2024 | 258,000.00 |